Chapter 2: Biological Risk Assessment
Laboratory directors and principal investigators should use risk assessment to alert their staffs to the hazards of working with infectious agents and to the need for developing proficiency in the use of selected safe practices and containment equipment. Successful control of hazards in the laboratory also protects persons not directly associated with the laboratory, such as other occupants of the same building, and the public.
Risk assessment requires careful judgment. Adverse consequences are more likely to occur if the risks are underestimated. By contrast, imposition of safeguards more rigorous than actually needed may result in additional expense and burden for the laboratory, with little safety enhancement. Unnecessary burden may result in circumvention of required safeguards. However, where there is insufficient information to make a clear determination of risk, it is prudent to consider the need for additional safeguards until more data are available.
The primary factors to consider in risk assessment and selection of precautions fall into two broad categories: agent hazards and laboratory procedure hazards. In addition, the capability of the laboratory staff to control hazards must be considered. This capability will depend on the training, technical proficiency, and good habits of all members of the laboratory, and the operational integrity of containment equipment and facility safeguards.
The agent summary statements contained in BMBL identify the primary agent and procedure hazards for specific pathogens and recommend precautions for their control. The guest editors and contributors of this and previous editions of BMBL based their recommendations on an assessment of the risks associated with the handling of pathogens using generally routine generic laboratory procedures. A review of the summary statement for a specific pathogen is a helpful starting point for assessment of the risks of working with that agent and those for a similar agent.
|Risk Group Classification||NIH Guidelines for Research Involving Recombinant DNA Molecules 2002||World Health Organization Laboratory Biosafety Manual 3rd Edition 2004|
|Risk Group 1||Agents that are not associated with disease in healthy adult humans.||(No or low individual and community risk) A microorganism that is unlikely to cause human or animal disease.|
|Risk Group 2||Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available.||(Moderate individual risk; low community risk) A pathogen that can cause human or animal disease but is unlikely to be a serious hazard to laboratory workers, the community, livestock or the environment. Laboratory exposures may cause serious infection, but effective treatment and preventive measures are available and the risk of spread of infection is limited.|
|Risk Group 3||Agents that are associated with serious or lethal human disease for which preventive or therapeutic interventions may be available (high individual risk but low community risk).||(High individual risk; low community risk) A pathogen that usually causes serious human or animal disease but does not ordinarily spread from one infected individual to another. Effective treatment and preventive measures are available.|
|Risk Group 4||Agents that are likely to cause serious or lethal human disease for which preventive or therapeutic interventions are not usually available (high individual risk and high community risk).||(High individual and community risk) A pathogen that usually causes serious human or animal disease and that can be readily transmitted from one individual to another, directly or indirectly. Effective treatment and preventive measures are not usually available.|
The predominant probable routes of transmission in the laboratory are:
- direct skin, eye or mucosal membrane exposure to an agent
- parenteral inoculation by a syringe needle or other contaminated sharp, or by bites from infected animals and arthropod vectors
- ingestion of liquid suspension of an infectious agent, or by contaminated hand to mouth exposure
- inhalation of infectious aerosols
An awareness of the routes of transmission for the natural human disease is helpful in identifying probable routes of transmission in the laboratory and the potential for any risk to the public health. For example, transmission of infectious agents can occur by direct contact with discharges from respiratory mucous membranes of infected persons, which would be a clear indication that a laboratory worker is at risk of infection from mucosal membrane exposure to droplets generated while handling that agent. The American Public Health Association publication Control of Communicable Diseases Manual is an excellent reference for identifying both natural and often noted laboratory modes of transmission. However, it is important to remember that the nature and severity of disease caused by a laboratory infection and the probable laboratory route of transmission of the infectious agent may differ from the route of transmission and severity associated with the naturally-acquired disease.
An agent capable of transmitting disease through respiratory exposure to infectious aerosols is a serious laboratory hazard, both for the person handling the agent and for other laboratory occupants. This hazard requires special caution because infectious aerosols may not be a recognized route of transmission for the natural disease. Infective dose and agent stability are particularly important in establishing the risk of airborne transmission of disease. For example, the reports of multiple infections in laboratories associated with the use of Coxiella burnetii are explained by its low inhalation infective dose, which is estimated to be ten inhaled infectious particles, and its resistance to environmental stresses that enables the agent to survive outside of a living host or culture media long enough to become an aerosol hazard.
When work involves the use of laboratory animals, the hazardous characteristics of zoonotic agents require careful consideration in risk assessment. Evidence that experimental animals can shed zoonotic agents and other infectious agents under study in saliva, urine, or feces is an important indicator of hazard. The death of a primate center laboratory worker from Cercopithecine herpesvirus 1 (CHV-1, also known as monkey B virus) infection following an ocular splash exposure to biologic material from a rhesus macaque emphasizes the seriousness of this hazard. Lack of awareness for this potential hazard can make laboratory staff vulnerable to an unexpected outbreak involving multiple infections. Experiments that demonstrate transmission of disease from an infected animal to a normal animal housed in the same cage are reliable indicators of hazard. Experiments that do not demonstrate transmission, however, do not rule out hazard. For example, experimental animals infected with Francisella tularensis, Coxiella burnetii, Coccidioides immitis, or Chlamydia psittaci, agents that have caused many LAIs, rarely infect cage mates.
The origin of the agent is also important in risk assessment. Non-indigenous agents are of special concern because of their potential to introduce risk of transmission, or spread of human and animal or infectious diseases from foreign countries into the United States. Importation of etiological agents of human disease requires a permit from the CDC. Importation of many etiological agents of livestock, poultry and other animal diseases requires a permit from the USDA’s Animal and Plant Health Inspection Service (APHIS). For additional details see Chapter 14.
Genetically-modified agent hazards
The identification and assessment of hazardous characteristics of genetically modified agents involve consideration of the same factors used in risk assessment of the wild-type organism. It is particularly important to address the possibility that the genetic modification could increase an agent’s pathogenicity or affect its susceptibility to antibiotics or other effective treatments. The risk assessment can be difficult or incomplete, because important information may not be available for a newly engineered agent. Several investigators have reported that they observed unanticipated enhanced virulence in recent studies with engineered agents. These observations give reason to remain alert to the possibility that experimental alteration of virulence genes may lead to increased risk. It also suggests that risk assessment is a continuing process that requires updating as research progresses.
The NIH Guidelines are the key reference in assessing risk and establishing an appropriate biosafety level for work involving recombinant DNA molecules. The purpose of the NIH Guidelines is to promote the safe conduct of research involving recombinant DNA. The guidelines specify appropriate practices and procedures for research involving constructing and handling both recombinant DNA molecules and organisms and viruses that contain recombinant DNA. They define recombinant DNA as a molecule constructed outside of a living cell with the capability to replicate in a living cell. The NIH Guidelines explicitly address experiments that involve introduction of recombinant DNA into Risk Groups 2, 3, and 4 agents, and experiments in which the DNA from Risk Groups 2, 3, and 4 agents is cloned into nonpathogenic prokaryotic or lower eukaryotic host-vector systems. Compliance with the NIH Guidelines is mandatory for investigators conducting recombinant DNA research funded by the NIH or performed at, or sponsored by, any public or private entity that receives any NIH funding for recombinant DNA research. Many other institutions have adopted these guidelines as the best current practice.
The NIH Guidelines were first published in 1976 and are revised on an ongoing basis in response to scientific and policy developments. They outline the roles and responsibilities of various entities affiliated with recombinant DNA research, including institutions, investigators, and the NIH. Recombinant DNA research subject to the NIH Guidelines may require:
- approval by the NIH Director, review by the NIH Recombinant DNA Advisory Committee (RAC), and approval by the IBC
- review by the NIH Office of Biotechnology Activities (OBA) and approval by the IBC
- review by the RAC and approvals by the IBC and Institutional Review Board
- approval by the IBC prior to initiation of the research
- notification of the IBC simultaneous with initiation of the work
It is important to note that review by an IBC is required for all non-exempt experiments as defined by the NIH Guidelines.
The NIH Guidelines were the first documents to formulate the concept of an IBC as the responsible entity for biosafety issues stemming from recombinant DNA research. The NIH Guidelines outlines the membership, procedures, and functions of an IBC. The institution is ultimately responsible for the effectiveness of the IBC, and may define additional roles and responsibilities for the IBC apart from those specified in the NIH Guidelines. See Chapter 18 for more information about the NIH Guidelines and OBA.
Workers who handle or manipulate human or animal cells and tissues are at risk for possible exposure to potentially infectious latent and adventitious agents that may be present in those cells and tissues. This risk is well understood and illustrated by the reactivation of herpes viruses from latency, the inadvertent transmission of disease to organ recipients, and the persistence of human immunodeficiency virus (HIV), HBV, and hepatitis C virus (HCV) within infected individuals in the U.S. population. There also is evidence of accidental transplantation of human tumor cells to healthy recipients which indicates that these cells are potentially hazardous to laboratory workers who handle them. In addition, human and animal cell lines that are not well characterized or are obtained from secondary sources may introduce an infectious hazard to the laboratory. For example, the handling of nude mice inoculated with a tumor cell line unknowingly infected with lymphocytic choriomeningitis virus resulted in multiple LAIs. The potential for human cell lines to harbor a bloodborne pathogen led the Occupational Health and Safety Administration (OSHA) to interpret that the occupational exposure to bloodborne pathogens final rule would include human cell lines.
Aerosols are a serious hazard because they are ubiquitous in laboratory procedures, are usually undetected, and are extremely pervasive, placing the laboratory worker carrying out the procedure and other persons in the laboratory at risk of infection. There is general agreement among biosafety professionals, laboratory directors and principal investigators who have investigated LAIs that an aerosol generated by procedures and operations is the probable source of many LAIs, particularly in cases involving workers whose only known risk factor was that they worked with an agent or in an area where that work was done.
Procedures that impart energy to a microbial suspension will produce aerosols. Procedures and equipment used routinely for handling infectious agents in laboratories, such as pipetting, blenders, non-self contained centrifuges, sonicators and vortex mixers are proven sources of aerosols. These procedures and equipment generate respirable-size particles that remain airborne for protracted periods. When inhaled, these particles are retained in the lungs creating an exposure hazard for the person performing the operation, coworkers in the laboratory, and a potential hazard for persons occupying adjacent spaces open to air flow from the laboratory. A number of investigators have determined the aerosol output of common laboratory procedures. In addition, investigators have proposed a model for estimating inhalation dosage from a laboratory aerosol source. Parameters that characterize aerosol hazards include an agent’s inhalation infective dose, its viability in an aerosol, aerosol concentration, and particle size.
Procedures and equipment that generate respirable size particles also generate larger size droplets that can contain multiple copies of an infectious agent. The larger size droplets settle out of the air rapidly, contaminating the gloved hands and work surface and possibly the mucous membranes of the persons performing the procedure. An evaluation of the release of both respirable particles and droplets from laboratory operations determined that the respirable component is relatively small and does not vary widely; in contrast hand and surface contamination is substantial and varies widely. The potential risk from exposure to droplet contamination requires as much attention in a risk assessment as the respirable component of aerosols.
Technique can significantly impact aerosol output and dose. The worker who is careful and proficient will minimize the generation of aerosols. A careless and hurried worker will substantially increase the aerosol hazard. For example, the hurried worker may operate a sonic homogenizer with maximum aeration whereas the careful worker will consistently operate the device to assuring minimal aeration. Experiments show that the aerosol burden with maximal aeration is approximately 200 times greater than aerosol burden with minimal aeration. Similar results were shown for pipetting with bubbles and with minimal bubbles. Containment and good laboratory practices also reduce this risk.
There may be hazards that require specialized personal protective equipment in addition to safety glasses, laboratory gowns, and gloves. For example, a procedure that presents a splash hazard may require the use of a mask and a face shield to provide adequate protection. Inadequate training in the proper use of personal protective equipment may reduce its effectiveness, provide a false sense of security, and could increase the risk to the laboratory worker. For example, a respirator may impart a risk to the wearer independent of the agents being manipulated.
Safety equipment such as Biological Safety Cabinets (BSC), centrifuge safety cups, and sealed rotors are used to provide a high degree of protection for the laboratory worker from exposure to microbial aerosols and droplets. Safety equipment that is not working properly is hazardous, especially when the user is unaware of the malfunction. The containment capability of a BSC is compromised by poor location, room air currents, decreased airflow, leaking filters, raised sashes, crowded work surfaces, and poor user technique. The safety characteristics of modern centrifuges are only effective if the equipment is operated properly. Training in the correct use of equipment, proper procedure, routine inspections and potential malfunctions, and periodic re-certification of equipment, as needed, is essential.
Facility safeguards help prevent the accidental release of an agent from the laboratory. Their use is particularly important at BSL-3 and BSL-4 because the agents assigned to those levels can transmit disease by the inhalation route or can cause life-threatening disease. For example, one facility safeguard is directional airflow. This safeguard helps to prevent aerosol transmission from a laboratory into other areas of the building. Directional airflow is dependent on the operational integrity of the laboratory’s heating, ventilation, and air conditioning (HVAC) system. HVAC systems require careful monitoring and periodic maintenance to sustain operational integrity. Loss of directional airflow compromises safe laboratory operation. BSL-4 containment facilities provide more complex safeguards that require significant expertise to design and operate.
Consideration of facility safeguards is an integral part of the risk assessments. A biological safety professional, building and facilities staff, and the IBC should help assess the facility’s capability to provide appropriate protection for the planned work, and recommend changes as necessary. Risk assessment may support the need to include additional facility safeguards in the construction of new or renovation of old BSL-3 facilities.
Identify agent hazards and perform an initial assessment of risk.
Consider the principal hazardous characteristics of the agent, which include its capability to infect and cause disease in a susceptible human host, severity of disease, and the availability of preventive measures and effectivetreatments.
There are several excellent resources that provide information and guidance for making an initial risk assessment. The BMBL provides agent summary statements for some agents associated with LAIs or are of increased public concern. Agent summary statements also identify known and suspected routes of transmission of laboratory infection and, when available, information on infective dose, host range, agent stability in the environment, protective immunizations, and attenuated strains of the agent.
A thorough examination of the agent hazards is necessary when the intended use of an agent does not correspond with the general conditions described in the Summary Statement or when an agent summary statement is not available. Although a summary statement for one agent may provide helpful information for assessing the risk of a similar agent, it should not serve as the primary resource for making the risk determination for that agent. Refer to other resources for guidance in identifying the agent hazards.
The Control of Communicable Diseases Manual provides information on communicable diseases including concise summaries on severity, mode of transmission, and the susceptibility and resistance of humans to disease. In addition, it is always helpful to seek guidance from colleagues with experience in handling the agent and from biological safety professionals.
Often there is not sufficient information to make an appropriate assessment of risk. For example, the hazard of an unknown agent that may be present in a diagnostic specimen will be unknown until after completing agent identification and typing procedures. It would be prudent in this case to assume the specimen contains an agent presenting the hazardous classification that correlates with BSL-2 unless additional information suggests the presence of an agent of higher risk. Identification of agent hazards associated with newly emergent pathogens also requires judgments based on incomplete information. Consult interim biosafety guidelines prepared by the CDC and the WHO for risk assessment guidance. When assessing the hazards of a newly attenuated pathogen, experimental data should support a judgment that the attenuated pathogen is less hazardous than the wild-type parent pathogen before making any reduction in the containment recommended for that pathogen.
Make a preliminary determination of the biosafety level that best correlates with the initial risk assessment based on the identification and evaluation of the agent hazards. Remember that aerosol and droplet routes of agent transmission also are important considerations in specification of safety equipment and facility design that result in a given BSL level.
Identify laboratory procedure hazards.
The principal laboratory procedure hazards are agent concentration, suspension volume, equipment and procedures that generate small particle aerosols and larger airborne particles (droplets), and use of sharps. Procedures involving animals can present a number of hazards such as bites and scratches, exposure to zoonotic agents, and the handling of experimentally generated infectious aerosols.
The complexity of a laboratory procedure can also present a hazard. The agent summary statement provides information on the primary laboratory hazards associated with typically routine procedures used in handling an agent. In proposed laboratory procedures where the procedure hazards differ from the general conditions of the agent summary statement or where an agent summary statement is not available, the risk assessment should identify specific hazards associated with the procedures.
Make a final determination of the appropriate biosafety level and select additional precautions indicated by the risk assessment.
The final selection of the appropriate biosafety level and the selection of any additional laboratory precautions require a comprehensive understanding of the practices, safety equipment, and facility safeguards described in Chapters 3, 4, and 5 of this manual.
There will be situations where the intended use of an agent requires greater precautions than those described in the agent’s Summary Statement. These situations will require the careful selection of additional precautions. An obvious example would be a procedure for exposing animals to experimentally generated infectious aerosols.
It is unlikely that a risk assessment would indicate a need to alter the recommended facility safeguards specified for the selected biosafety level. If this does occur, however, it is important that a biological safety professional validate this judgment independently before augmenting any facility secondary barrier.
It is also important to recognize that individuals in the laboratory may differ in their susceptibility to disease. Pre-existing diseases, medications, compromised immunity, and pregnancy or breast-feeding that may increase exposure to infants to certain agents, are some of the conditions that may increase the risk of an individual for acquiring a LAI. Consultation with an occupational physician knowledgeable in infectious diseases is advisable in these circumstances.
Evaluate the proficiencies of staff regarding safe practices and the integrity of safety equipment.
The protection of laboratory workers, other persons associated with the laboratory, and the public will depend ultimately on the laboratory workers themselves. In conducting a risk assessment, the laboratory director or principal investigator should ensure that laboratory workers have acquired the technical proficiency in the use of microbiological practices and safety equipment required for the safe handling of the agent, and have developed good habits that sustain excellence in the performance of those practices. An evaluation of a person’s training, experience in handling infectious agents, proficiency in the use of sterile techniques and BSCs, ability to respond to emergencies, and willingness to accept responsibility for protecting one’s self and others is important insurance that a laboratory worker is capable of working safely.
The laboratory director or principal investigator should also ensure that the necessary safety equipment is available and operating properly. For example, a BSC that is not certified represents a potentially serious hazard to the laboratory worker using it and to others in the laboratory. The director should have all equipment deficiencies corrected before starting work with an agent.
Review the risk assessment with a biosafety professional, subject matter expert, and the IBC.
A review of the risk assessment and selected safeguards by knowledgeable individuals is always beneficial and sometimes required by regulatory or funding agencies, as is the case with the NIH Guidelines. Review of potentially high risk protocols by the local IBC should become standard practice. Adopting this step voluntarily will promote the use of safe practices in work with hazardous agents in microbiological and biomedical laboratories.
New knowledge and experiences may justify altering these safeguards. Risk assessment, however, must be the basis for recommended change. Assessments conducted by laboratory directors and principal investigators for the use of emergent agents and the conduct of novel experiments will contribute to our understanding of the risks these endeavors may present and the means for their control. Those risk assessments will likely mirror progress in science and technology and serve as the basis for future revisions of BMBL.